

NeuroMetrix CEO Dr. Shai N. Gozani Interviewed Live on TuDiabetes.org

Discussion of Diagnosis and Treatment of Diabetic Peripheral Neuropathy

WALTHAM, Mass.--(BUSINESS WIRE)-- Shai N. Gozani, M.D., Ph.D, President and Chief Executive Officer of NeuroMetrix, Inc. (Nasdaq: NURO), a medical device company focused on the treatment and management of the neurological complications of diabetes, was interviewed live on the <u>TuDiabetes.org</u> website yesterday, March 6, 2014. <u>TuDiabetes.org</u> is a community of people touched by diabetes and is a program of the Diabetes Hands Foundation.

During the live interview, Dr. Gozani provided answers to a range of questions from the <u>TuDiabetes.org</u> community about the diagnosis and treatment of diabetic peripheral neuropathy or DPN. Additionally, he discussed a range of available tests such as the company's DPNCheck[®] device, a rapid, accurate, and quantitative point-of-care test for diabetic neuropathy, as well as various treatment options including the company's SENSUSTM Pain Management System for treating chronic intractable pain such as painful diabetic neuropathy.

To view the interview in its entirety, please visit the following link: http://youtu.be/JPJ7BSA66Hk

About NeuroMetrix

NeuroMetrix is a medical device company that develops and markets home use and point-of-care devices for the treatment and management of chronic pain, peripheral neuropathies, and associated neurological disorders. The Company is presently focused on diabetic neuropathies, which affect over 50% of people with diabetes. If left untreated, diabetic neuropathies trigger foot ulcers that may require amputation and cause disabling chronic pain. The annual cost of diabetic neuropathies has been estimated at \$14 billion in the United States. The company markets the SENSUS[™] Pain Management System for treating chronic pain, focusing on physicians managing patients with painful diabetic neuropathy. The company also markets the DPNCheck[®] device, which is a rapid, accurate, and quantitative point-of-care test for diabetic neuropathy. This product is used to detect diabetic neuropathy at an early stage and to guide treatment. For more information, please visit http://www.DPNCheck.com.

NeuroMetrix, Inc.
Thomas T. Higgins, 781-314-2761
SVP and Chief Financial Officer
neurometrix.ir@neurometrix.com

Source: NeuroMetrix, Inc.

News Provided by Acquire Media